Valued at a market cap of $25.1 billion, IQVIA Holdings Inc. (IQV) is a global provider of clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries. The company operates through Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions segments.

Shares of IQV have underperformed the broader market over the past 52 weeks. IQV has crumbled 37% over this period, while the broader S&P 500 Index ($SPX) has gained 11.9%. Moreover, shares of IQV are down 26.2% on a YTD basis, compared to SPX’s 1% return.

Zooming in further, the Durham, North Carolina-based company has also lagged behind the Healthcare Select Sector SPDR ETF Fund’s (XLV) 7.7% drop over the past 52 weeks and 2.1% decline on a YTD basis.

IQVIA stock prices fell 4% following the release of its Q1 2025 earnings on May 6. The company reported revenue of $3.8 billion, up 2.5% year-over-year, surpassing the consensus estimate. Its adjusted EBITDA increased 2.4% from the year-ago quarter to $883 million. Adjusted EPS came in at $2.70, a 6.3% rise from the prior-year quarter. 

Looking ahead, IQV expects full-year 2025 revenue to range between $16 billion and $16.4 billion, with adjusted EPS projected between $11.70 and $12.10. 

For the fiscal year ending in December 2025, analysts expect IQV’s adjusted EPS to increase nearly 5% year-over-year to $10.76. The company's earnings surprise history is mixed. It beat the consensus estimates in three of the past four quarters while missing on another occasion.

Among the 22 analysts covering the stock, the consensus rating is a “Strong Buy.” That’s based on 15 “Strong Buy” ratings, two “Moderate Buys,” and five “Holds.” 

This configuration is less bullish than three months ago, with 17 “Strong Buy” ratings on the stock.

On May 19, JP Morgan analyst Anne Samuel lowered IQV's price target to $177 while maintaining an “Overweight” rating on the stock. 

As of writing, IQVIA is trading below the mean price target of $196.41. The Street-high price target of $270 implies a potential upside of a staggering 86.3% from the current price levels.